Kaleido Biosciences to Present at the 38th Annual J.P. Morgan Healthcare Conference

LEXINGTON, Mass., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. KLDO, a clinical-stage healthcare company with a chemistry-driven approach to leveraging the microbiome organ to treat disease and improve human health, today announced that Alison Lawton, President and Chief Executive Officer, will present at the 38^th Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2020 at 4:00 p.m. PT (7:00 p.m. ET) in San Francisco, CA.

A live audio webcast of the presentation and question and answer session can be accessed on the Investors & Media section of Kaleido's website at https://investors.kaleido.com/events-presentations. An archived replay will be available for 30 days following the event.

About Kaleido Biosciences

Kaleido Biosciences is a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging the microbiome organ to treat disease and improve human health. The Company has built a human-centric proprietary product platform to enable the rapid and cost-efficient discovery and development of novel Microbiome Metabolic Therapies (MMT™). MMTs are designed to modulate the metabolic output and profile of the microbiome by driving the function and distribution of the organ's existing microbes. Kaleido is advancing a broad pipeline of MMT candidates with the potential to address a variety of diseases and conditions with significant unmet patient needs. To learn more, visit https://kaleido.com/.

Contact

Amy Reilly

617-890-5721

amy.reilly@kaleido.com